Abiopharma

🔍 Kumar Nisha (Director)

Company: Western Asset Diversified Income Fund (WDI) (WDI)

Report Date: 2026-08-10

Detailed Transactions and Holdings:

• Sold 9,000 shares of Common Stock at $13.12 per share (Direct)
  Date: 2026-08-10 | Code: S | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
• Sold 3,225 shares of Common Stock at $13.155 per share (Direct)
  Date: 2026-08-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 17,411.79 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 3,750 shares of Common Stock at $13.1422 per share (Direct)
  Date: 2026-08-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 13,661.79 | transaction_form_type: 4 | Footnotes: F3
• Sold 6,912 shares of Common Stock at $13.1349 per share (Direct)
  Date: 2026-08-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 6,750.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: The price reported in column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $13.08 to $13.13, inclusive. Ms. Kumar undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request full information regarding the number of shares sold at each separate price within the range set forth above.
• F2: This amount reflects an adjustment after a reconciliation of the Reporting Person's records.
• F3: These shares of Common Stock are held by account for the benefit of Ms. Kumar's family. Pursuant to Rule 16a-1(a)(4) under the Exchange Act, the Reporting Person states that this filing shall not be an admission that the Reporting Person is the beneficial owner of any of the securities reported herein, and the Reporting Person disclaims beneficial ownership of such securities except to the extent of the Reporting Person's pecuniary interest therein.